SW · BSLN.SW
Basilea Pharmaceutica AG
- Sector
- Healthcare · Biotechnology
- Headquarters
- Allschwil 4058
- Website
- basilea.com
Price · as of 2025-12-31
$54.40
Market cap 670.03M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $86.27 | +58.58% |
| Intrinsic Value(DCF) | $35.17 | -35.35% |
| Graham-Dodd Method(GD) | $26.92 | -50.51% |
| Graham Formula(GF) | $62.62 | +15.12% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $46.37 | $257.23 | $201.34 | $0.00 | $197.30 |
| 2012 | $53.69 | $429.95 | $5.77 | $0.00 | $17.46 |
| 2013 | $108.00 | $161.95 | $3.55 | $0.00 | $69.27 |
| 2014 | $113.40 | $53.35 | $1.79 | $0.00 | $0.00 |
| 2015 | $72.00 | $48.15 | $0.00 | $0.00 | $0.00 |
| 2016 | $90.75 | $50.23 | $0.00 | $0.00 | $0.00 |
| 2017 | $66.55 | $223.72 | $0.00 | $0.00 | $0.00 |
| 2018 | $48.64 | $692.34 | $1.72 | $0.00 | $0.00 |
| 2019 | $35.28 | $38.01 | $0.00 | $0.00 | $0.00 |
| 2020 | $47.32 | $44.31 | $0.00 | $0.00 | $0.00 |
| 2021 | $37.46 | $46.92 | $0.07 | $0.00 | $0.00 |
| 2022 | $50.20 | $194.12 | $0.67 | $3.37 | $8.13 |
| 2023 | $35.60 | $45.60 | $4.67 | $3.52 | $12.59 |
| 2024 | $47.35 | $119.91 | $48.08 | $38.79 | $249.86 |
| 2025 | $54.60 | $86.27 | $57.18 | $26.92 | $62.62 |
AI valuation
Our deep-learning model estimates Basilea Pharmaceutica AG's (BSLN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $86.27
- Current price
- $54.40
- AI upside
- +58.58%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$35.17
-35.35% upside
Graham-Dodd
$26.92
-50.51% upside
Graham Formula
$62.62
+15.12% upside
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
- CEO
- David Veitch
- Employees
- 164
- Beta
- 0.45
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($35.17 ÷ $54.40) − 1 = -35.35% (DCF, example).